Monte Rosa Therapeutics, Inc. Marketable Securities, Gain (Loss)
Monte Rosa Therapeutics, Inc. (GLUE) reported Marketable Securities, Gain (Loss) of $0 for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesGainLoss · last filed 2024-05-09
- Monte Rosa Therapeutics, Inc. marketable securities, gain (loss) for the quarter ending 2024-03-31 was $0.00.
- Monte Rosa Therapeutics, Inc. marketable securities, gain (loss) for the quarter ending 2023-12-31 was $0.00.
- Monte Rosa Therapeutics, Inc. marketable securities, gain (loss) for the quarter ending 2023-09-30 was $0.00.
- Monte Rosa Therapeutics, Inc. marketable securities, gain (loss) for the quarter ending 2023-06-30 was $0.00.
- Monte Rosa Therapeutics, Inc. marketable securities, gain (loss) for fiscal 2023 was -$131.00K.
- Monte Rosa Therapeutics, Inc. marketable securities, gain (loss) for fiscal 2022 was $0.00.
| Period end | Marketable Securities, Gain (Loss) 3 month | Marketable Securities, Gain (Loss) 6 month | Marketable Securities, Gain (Loss) 9 month | Marketable Securities, Gain (Loss) 12 month |
|---|---|---|---|---|
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-05-09 | $0.00 derived: sum of 3 quarters · filed 2024-05-09 | $0.00 derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $0.00 derived: sum of 3 quarters · filed 2024-03-14 | -$131.00K 10-K · filed 2024-03-14 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | -$131.00K 10-Q · filed 2023-11-09 | -$131.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-10 | -$131.00K 10-Q · filed 2023-08-10 | -$131.00K derived: sum of 3 quarters · filed 2024-05-09 | -$131.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-03-31 | -$131.00K 10-Q · filed 2024-05-09 | -$131.00K derived: sum of 2 quarters · filed 2024-05-09 | -$131.00K derived: sum of 3 quarters · filed 2024-05-09 | -$131.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $0.00 derived: sum of 3 quarters · filed 2024-03-14 | $0.00 10-K · filed 2024-03-14 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |